Wednesday, November 27, 2019 8:34:57 PM
p.s. AXSM claims that the two constituent drugs have synergistic pharmacokinetics, and I’m not disputing that.
Exactly. So absent other factors such as unexpected placebo response or compliance issues during the trial or any other unknowns, not sure for less than acceptable odds for the trail to succeed.
Finally I think the management has the data on hand and will be PR'd soon. Why else they would have KOL/Investor's meeting? Just reading the tea leaves here
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
